novo nordisk glp-1 Ozempic is first drug FDA-approved for kidney disease A New Era of Weight
Description
PMID: 37288303
Explore the role of GLP-1 receptor agonists in neuroprotection and their impact on Alzheimer's and Parkinson's diseases.
Glucagon-like peptide-1 receptor agonists, namely GLP-1 receptor agonists, are a class of drugs for the treatment of type 2 diabetes.
This landmark policy change recognises obesity as a chronic disease and recommends that GLP-1 antagonists are used by adults for the long-term treatment of obesity
PHILADELPHIA While celebrities and diabetes patients alike have heralded the swift success of Ozempic and similar drugs, more than 900 complaints...
